John M. Evans - 31 Jan 2023 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Reporting relationship: CEO, Director
Issuer ticker: BEAM
Reported as of: 31 Jan 2023
Net transaction value: +$99,997
SEC form: 4
Accepted by SEC: 31 Mar 2023, 19:48:43 UTC
Prior SEC filing: 02 Nov 2022
Next SEC filing: 05 Apr 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Christine Bellon, Attorney-in-fact

Key filing fact

John M. Evans filed Form 4 for Beam Therapeutics Inc. (BEAM) on 31 Mar 2023.

Key facts

This page summarizes John M. Evans's Form 4 filing for Beam Therapeutics Inc. (BEAM).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 31 Mar 2023, 19:48.

Change

Previous filing in this sequence was filed on 02 Nov 2022.
Current net transaction value: +$99,997.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BEAM transaction

Common Stock

Small acquisition under Rule 16a-6

Transaction value: $0
Shares: +225
Change %: +0.02%
Price: $0.000000
Shares after: 1,059,053
Date: 06 Mar 2023
Ownership: Direct
Footnotes: F1, F2

BEAM transaction

Common Stock

Award

Transaction value: $0
Shares: +56,250
Change %: +5.3%
Price: $0.000000
Shares after: 1,115,303
Date: 31 Mar 2023
Ownership: Direct
Footnotes: F3

BEAM transaction

Common Stock

Options Exercise

Transaction value: $99,997
Shares: +13,850
Change %: +1.2%
Price: $7.22
Shares after: 1,129,153
Date: 31 Mar 2023
Ownership: Direct

BEAM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 103,000
Date: 31 Jan 2023
Ownership: By John M. Evans, III 2018 Irrevocable Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BEAM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +112,500
Change %
Price: $0.000000
Shares after: 112,500
Date: 31 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 112,500
Exercise price: $43.45
Footnotes: F4

BEAM transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -13,850
Change %: -6.6%
Price: $0.000000
Shares after: 196,904
Date: 31 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,850
Exercise price: $7.22
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Distribution of Beam Therapeutics Inc. ("BEAM") common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration.

Footnote F2

Includes 308 shares and acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2022.

Footnote F3

Represents restricted stock units ("RSUs") granted to the Reporting Person under BEAM's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

Footnote F4

This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date.

Footnote F5

This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. ..